Bio-Rad Launches Vericheck ddPCR Kit Portfolio for Cell and Gene Therapy Quality Control on QX700 Platform
核心洞察
Bio-Rad Laboratories (搜索) has launched a new portfolio of Vericheck ddPCR Kits compatible with the QX700 System for critical quality control workflows in cell and gene therapy development.
The portfolio includes five validated kits covering mycoplasma detection, empty-full capsid analysis, replication-competent lentivirus testing, and residual DNA quantification for CHO and E. coli.
The QX700 platform enables seven-color multiplexing and can process up to 384 reactions in approximately 2.5 hours with minimal input volume and continuous loading capability.
Bio-Rad Laboratories (搜索) has announced the launch of the QX700 System-compatible Vericheck ddPCR Kit portfolio, designed to address critical quality control (QC) workflows in advanced cell and gene therapy development and other biopharma applications. The announcement, made by the global leader in life science research and clinical diagnostics products, marks a significant expansion of the company's digital droplet PCR (ddPCR) offerings tailored to the stringent demands of advanced therapeutic manufacturing.
The new portfolio comprises five application-focused, validated kits: Vericheck ddPCR Mycoplasma Detection, Empty-Full Capsid, Replication Competent Lentivirus, CHO Residual DNA Quantification, and E. coli Residual DNA Quantification kits. These ready-to-use kits extend Bio-Rad's existing ddPCR platform portfolio, providing researchers and manufacturers with validated workflows for high-priority QC testing needs.
Addressing Critical QC Challenges in Advanced Therapies
In advanced therapeutic development and manufacturing, QC testing is critical to ensure the safety and effectiveness of the product. The newly launched Vericheck Kits provide validated workflows to improve confidence in vector characterization and contamination detection, including replication-competent virus testing and residual host cell DNA quantification. These are essential parameters for regulatory compliance and product release in the cell and gene therapy space.
Stephen Kulisch, Vice President of Marketing, Digital Biology Group at Bio-Rad, stated: "The expansion of our range of Vericheck ddPCR Kits offers validated workflows with unmatched precision and sensitivity, combined with the power of the QX700 platform, enabling scalable, streamlined workflows and faster time to actionable results." He added: "By expanding the power of our QX700 platform through the development of this new portfolio of Vericheck Kits, Bio-Rad is continuing its commitment to support development of safer and more efficient advanced therapeutic development and manufacturing."
QX700 Platform Capabilities
The QX700 platform serves as the analytical backbone for the new kit portfolio, offering seven-color multiplexing and the capacity to process up to 384 reactions in approximately two and a half hours. The system features minimal input volume requirements, continuous loading capability, and easy-to-use software for streamlined data interpretation. By combining the performance of the QX700 Systems with the Vericheck Kits, researchers can generate precise, reproducible, and faster results for product development, product safety, and product quality assessment.
The integration of validated kits with a high-throughput, multiplex-capable platform addresses a growing need in the biopharmaceutical industry for accessible, standardized QC solutions that can keep pace with accelerating development timelines in cell and gene therapy.